We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ultrasis | LSE:ULT | London | Ordinary Share | GB0001494979 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.095 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMULT
RNS Number : 5914T
Ultrasis PLC
07 October 2014
Ultrasis plc
("Ultrasis" or the "Company")
Board Changes and Financing Update
The Company announces that Gerald Malone and Michael Mills, who have been non-executive directors for 14 and 11 years respectively, have resigned with immediate effect. The Board thanks them for their years of service and valuable input.
John Smith, CEO, will become interim Executive Chairman following Gerald Malone's departure and the Company will now seek an alternative Chairman and non-executive director to provide an appropriate board structure.
As initially announced on 29 January 2013, the Company has loan facilities in place with Paul Bell, a substantial shareholder in the Company, of which approximately GBP700,000 was undrawn at the end of September 2014. Under the terms of the loan facilities, the Company is entitled to draw down funds to a maximum amount of GBP1 million in any rolling 12 month period, a limit the Company has already reached, However, Mr. Bell has recently written to the Company stating that he is prepared to continue to consider on-going requests for draw-downs under the loan facilities which are in excess of the rolling limit, subject to, inter alia, a review of the Company's short and medium term working capital requirements and the Board seeking cancellation of the Company's shares to trading on AIM.
Consequently, the Board intends shortly to send a circular to shareholders seeking the cancellation of the Company's shares to trading on AIM. Further announcements will be made in due course.
For all enquiries relating to Ultrasis please contact:
Ultrasis plc Tel: +44 (0) 20 7535 2050 John Smith, Interim Executive Chairman finnCap Ltd Tel: +44 (0) 20 7220 0500 Geoff Nash / Charlotte Stranner
Notes to Editors:
Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDGBDGXUGBGSL
1 Year Ultrasis Chart |
1 Month Ultrasis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions